As Johnson & Johnson continues to move out of the diabetes business, the company has sold its Calibra product (marketed as OneTouch Via, but never launched) to CeQur, a 10-year-old company working on a similar insulin-delivery wearable. Terms of the deal were not disclosed, but CeQur has acquired an exclusive worldwide license for the technology.
“They’re divesting out of the diabetes market...
